Advice

in the absence of a submission from the holder of the marketing authorisation:

pomalidomide (ImnovidĀ®) is not recommended for use within NHSScotland.

Indication under review: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice353KB (PDF)

Download

Medicine details

Medicine name:
pomalidomide (Imnovid)
SMC ID:
SMC2219
Indication:

In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
12 August 2019